NEWS

We are excited to share the news that NovoPedics' total meniscus replacement device currently in development recently received  Breakthrough Device Designation from the U.S. Food and Drug Administration.

Click to view:

Novopedics press release

Novopedics website 

FVCG invested in NovoPedics in 2013.

FVCG Sells Interest in Durin

We have sold our equity interest in Durin Technologies, Inc. (Durin) to Breakthrough Diagnostics, Inc. 

Durin was founded by Robert G. Nagele, PhD (pictured above), a professor and researcher at Rowan University School of Osteopathic Medicine, pursuing the development of blood tests to detect neurodegenerative diseases at very early stages. 

©2020 by Foundation Venture Capital Group